Patents Examined by Prema M Mertz
  • Patent number: 11185584
    Abstract: An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: November 30, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Jacqueline Benson, Mark Cunningham, Cynthia Duchala, Jill Giles-Komar, Jinquan Luo, Michael Rycyzyn, Raymond Sweet
  • Patent number: 11180549
    Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: November 23, 2021
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution, Inc
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David M. Marquis, David J. Shealy, Eric Michael Smith, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond Sweet, Susan Tam, Alain P. Vasserot, Sheng-Jiun Wu, Jing Yang
  • Patent number: 11180540
    Abstract: The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using chromatography to reduce amounts of certain aflibercept variants.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: November 23, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew Tustian, Ankit Vartak, Thomas Daly, Erica Pyles, Nisha Palackal, Shunhai Wang, Ning Li, Matthew Franklin
  • Patent number: 11180548
    Abstract: One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous Fc region variants that have decreased binding to pre-existing ADA. An alternative nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: November 23, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Tatsuhiko Tachibana, Yuki Iwayanagi, Yuji Hori, Genki Nakamura, Masaru Muraoka
  • Patent number: 11168134
    Abstract: The present invention provides a method of treatment of prostate cancer, comprising administering a therapeutically effective amount of an inhibitor of IL-23 and/or an inhibitor of IL-23R to a mammalian patient in need thereof. The prostate cancer may be castration resistant prostate cancer (CRPC). The inhibitor may, for example, be an anti-IL-23 antibody, such as risankizumab, guselkumab or tildrakizumab. The method of treatment may further comprise administration of androgen deprivation therapy, such as enzalutamide. Also provided is a method of predicting the development of resistance to androgen deprivation therapy (ADT) in a prostate cancer in a mammalian patient and a related screening method.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: November 9, 2021
    Assignees: FONDAZIONE PER L'ISTITUTO ONCOLOGICO DI RICERCA (IOR), THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
    Inventors: Andrea Alimonti, Arianna Calcinotto, Johann de Bono
  • Patent number: 11161890
    Abstract: The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-7 or IL-21.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: November 2, 2021
    Assignee: Altor Bioscience LLC.
    Inventor: Hing C. Wong
  • Patent number: 11155614
    Abstract: Provided are blocking agents to IL-1?, IL-1?, or IL-1R activity for use in combination with radiotherapy for treating cancer patients in which radiotherapy treatment induces IL-1?, IL-1? or both in their circulation.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: October 26, 2021
    Assignee: OncoHost Ltd.
    Inventors: Yuval Shaked, Eyal Jacob, Ella Fremder
  • Patent number: 11155588
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: October 26, 2021
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • Patent number: 11149089
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: October 19, 2021
    Assignee: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria-Laura Sargentini-Maier, Özkan Yalkinoglu
  • Patent number: 11137397
    Abstract: Methods and agents are provided for inhibiting interleukin 1 receptor accessory protein (IL1RAP) protein-protein interaction to treat a broad spectrum of diseases and conditions.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: October 5, 2021
    Assignee: Albert Einstein College of Medicine
    Inventors: Ulrich Steidl, Laura Barreyro De Pujato, Mario Pujato
  • Patent number: 11136388
    Abstract: Disclosed herein are safe doses of dual-V-region antibody-like binding proteins or fragments thereof, as well as methods for assessing binding of dual-V-region antibody-like proteins or fragments thereof to their targets, and methods of treating idiopathic pulmonary fibrosis (IPF) by administering safe doses of dual-V-region antibody-like binding proteins or fragments thereof. In some embodiments, the dual-V-region antibody-like binding proteins or fragments thereof bind both IL-4 and IL-13.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: October 5, 2021
    Assignee: SANOFI
    Inventors: Corinne Esperet, Alexandre Jagerschmidt, Christina Soubrane, Arun Subramaniam
  • Patent number: 11136366
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: October 5, 2021
    Assignee: Novartis AG
    Inventors: Michael DiDonato, Bernhard Hubert Geierstanger, Tobias Junt, Mark Knuth, Shelly Meeusen, Carolina Nicole Simpson, Glen Spraggon, John Trauger
  • Patent number: 11136367
    Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: October 5, 2021
    Assignee: Wake Forest University Health Sciences
    Inventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
  • Patent number: 11130806
    Abstract: The present invention relates to antibodies binding IL-15, in particular humanized antibodies. In particular, the anti-IL-15 antibodies according to the invention are able to neutralize IL-15 activity and are useful in the prevention and/or treatment of an autoimmune disease and/or inflammatory disorder, a malignancy, transplant rejection, metabolic condition and/or an infectious disease caused by parasitic, viral or bacterial pathogens.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: September 28, 2021
    Assignee: CALYPSO BIOTECH SA
    Inventors: Alain Vicari, Olivier Leger
  • Patent number: 11130792
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: September 28, 2021
    Assignee: Scott & White Memorial Hospital
    Inventor: Arthur E. Frankel
  • Patent number: 11129883
    Abstract: The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: September 28, 2021
    Assignee: Altor BioScience, LLC.
    Inventors: Warren D. Marcus, Robert Newman, Bai Liu, Lijing You, Lin Kong, Peter Rhode, Hing C. Wong
  • Patent number: 11122825
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through a high affinity interleukin receptor. The antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prevention of immune related disorders such as Type 1 Diabetes.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: September 21, 2021
    Assignee: Novartis AG
    Inventors: Yaiza Diaz-De-Durana, Michael DiDonato, Christophe Filippi, Shelly Meeusen, Glen Spraggon
  • Patent number: 11117958
    Abstract: Provided is an antibody that binds to human interleukin-2 (hIL-2), and more particularly to an anti-hIL-2 antibody that binds specifically to a particular epitope of hIL-2, thereby inhibiting the binding of the hIL-2 to CD25. The anti-hIL-2 antibody of the subject matter binds specifically to a particular epitope of hIL-2, thereby inhibiting the binding of the hIL-2 to CD25, thereby minimizing expansion of Treg cells. In addition, it stimulates the CD8+ T cells and NK cells that exhibit anti-tumor activity. Thus, the anti-hIL-2 antibody of the present invention is useful as a new anticancer therapeutic agent.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: September 14, 2021
    Assignees: INSTITUTE FOR BASIC SCIENCE, POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Charles D. Surh, Jun-Young Lee
  • Patent number: 11117943
    Abstract: Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: September 14, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kenan Christopher Garcia, Aron Levin, Aaron Ring
  • Patent number: 11117975
    Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: September 14, 2021
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Adam Clarke, Matthew Pollard, Anthony Gerard Doyle, Collette Behrens, Tetsuo Yamagishi, David S. Wilson, Jr., Sarah L. Pogue, Tetsuya Taura